Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Regina Paleski
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Executives On The Move: Global Aesthetics Head Exits Allergan for Merz, C-Level Commercial Changes at Flexion And Karyopharm
Merz Pharma Group’s Merz Aesthetics welcomes former Allergan exec as new chief scientific officer. Meanwhile, a chief commercial officer is appointed at Flexion Therapeutics, developer of treatments for musculoskeletal conditions, and at Karyopharm Therapeutics, an oncology-focused pharma.
Executives On The Move: UCB Announces Future Financial Leadership Change And Analytics Experience for Corbus Pharma
Corbus Pharmaceuticals, developer of therapeutics for inflammatory and fibrotic diseases, hires EMD Serono exec as head of commercial ops and analytics. Also, multinational biopharma UCB to have a new CFO in July.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Executives On The Move: Bayer Elects New Chairman, J&J Vision Exec Makes A Change for Eyevance And CureVac Decides On Candidate For Rare Diseases Post
Bayer AG elects a new chairman, to begin serving at the end of April. US ophthalmic products firm Eyevance Pharma brings on board a former J&J Vision exec as chief commercial officer, and German mRNA company CureVac AG appoints a new head of rare diseases.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.